Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 8.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 122,341 shares of the company’s stock after selling 10,637 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $7,271,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of TARS. Mirae Asset Global Investments Co. Ltd. increased its stake in Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after buying an additional 2,462 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Tarsus Pharmaceuticals by 220.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after buying an additional 2,782 shares during the last quarter. West Wealth Group LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at $202,000. Finally, Allianz Asset Management GmbH acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $227,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Trading Up 0.3%

Tarsus Pharmaceuticals stock opened at $68.15 on Wednesday. The firm has a market cap of $2.89 billion, a PE ratio of -33.74, a P/E/G ratio of 0.98 and a beta of 0.59. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The stock’s 50 day simple moving average is $78.32 and its two-hundred day simple moving average is $65.11. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. The firm had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. Analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TARS. Barclays initiated coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $100.00 price target on the stock. Zacks Research upgraded Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Mizuho began coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective for the company. Finally, Guggenheim upped their price objective on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.86.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.